ARCHIVES

Turmoil in Texas: DePinho Recommended AVEO Stock on CNBC Six Days After FDA Said New Trial Was Needed

This article is from The Cancer Letter archive.

Vol. 39 No. 19 | May 10, 2013

Download PDF Visit The Full Archive

Related Articles

Centocor Withdraws Yondelis After FDA Calls for New Study

April 29, 2011

NCI Beings Accelerated Review Of R01s That just Miss Payline

March 29, 1996

The Cancer Letter’s Paul Goldberg Wins Journalism Award

April 10, 2009

Study Opens For Women At Risk of Ovarian Cancer

October 29, 2004

NY Attorney General Sues Drug Companies Over Cancer Drug Pricing Deals

February 14, 2003

In Brief: Georgetown, Theurer Form Collaboration; Hopkins To Develop Bladder Cancer Institute

June 6, 2014